China will improve its oversight of human related scientific research and medical tests under draft laws and amendments submitted to China's top legislature for review on Saturday.
People involved in the production and sale of drugs will pay higher costs and face harsher penalties for malfeasance, under a draft amendment to the Drug Administration Law that was submitted to the Standing Committee of the National People's Congress, China's top legislative body, for review on Saturday.
China's top legislative body raised concerns on Saturday about a new AI technology that can digitally swap people's faces.
The service sector, IT and media industries have overtaken the education industry as major job sources for expats in China, according to figures from the 2019 Job Fair for Foreigners in Beijing.
More cooperative action is urgently needed by countries associated with the Belt and Road Initiative to mitigate the tax related obstacles in cross-border trade and investment, according to BRI tax authorities.
A Chinese company participating in the China-Laos transnational railway project has been making consistent efforts to ensure that the project will not be tainted by corruption, according to railway authorities.
In a large cement-block structure with its floor consisting of rows of mulberry leaves crawling with baby silkworms, Yin Shouquan from the Kunming University of Science and Technology in Yunnan province considers this to be his office.
An increasing number of countries have tapped into the convenience of e-visas to attract more tourists from China, the world's largest source of outbound tourists.
More than 2,000 artificial nests will be installed on power poles scattered in a nature reserve on the Qinghai-Tibet Plateau this year to protect wild birds and ensure electricity transmission.
Customs officers from Guangzhou, Guangdong province, have seized more than 178 kilograms of smuggled endangered animals and their products after cracking down on 111 smuggling cases since the beginning of the year.
A new therapy developed by Chinese researchers to treat bone marrow cancer has completed its first phase of clinical trials with a response rate of 90 percent.
|
|
|
|
|
|
|
|
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263 Registration Number: 20100000002731 
Raymond Zhou
Op Rana
Berlin Fang
Zhu Yuan
Huang Xiangyang
Chen Weihua
